Chas P. Smith & Associates (CPS)’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $924K | Hold |
4,249
| – | – | 0.05% | 78 |
|
|
2025
Q4 | $971K | Buy |
4,249
+1,100
| +35% | +$251K | 0.05% | 78 |
|
|
2025
Q3 | $729K | Sell |
3,149
-1,185
| -27% | -$241K | 0.06% | 69 |
|
|
2025
Q2 | $804K | Sell |
4,334
-99
| -2% | -$18.4K | 0.05% | 81 |
|
|
2025
Q1 | $929K | Sell |
4,433
-160
| -3% | -$31.1K | 0.05% | 77 |
|
|
2024
Q4 | $816K | Hold |
4,593
| – | – | 0.05% | 78 |
|
|
2024
Q3 | $907K | Buy |
4,593
+136
| +3% | +$25.4K | 0.05% | 73 |
|
|
2024
Q2 | $764K | Sell |
4,457
-23
| -0.5% | -$3.81K | 0.05% | 76 |
|
|
2024
Q1 | $816K | Buy |
4,480
+1,003
| +29% | +$173K | 0.05% | 73 |
|
|
2023
Q4 | $539K | Buy |
3,477
+29
| +0.8% | +$4.23K | 0.04% | 73 |
|
|
2023
Q3 | $514K | Sell |
3,448
-1,833
| -35% | -$269K | 0.04% | 69 |
|
|
2023
Q2 | $712K | Buy |
5,281
+670
| +15% | +$98.3K | 0.05% | 60 |
|
|
2023
Q1 | $735K | Sell |
4,611
-133
| -3% | -$20.3K | 0.05% | 57 |
|
|
2022
Q4 | $767K | Sell |
4,744
-307
| -6% | -$47.1K | 0.05% | 54 |
|
|
2022
Q3 | $678K | Sell |
5,051
-40
| -0.8% | -$5.74K | 0.06% | 55 |
|
|
2022
Q2 | $780K | Sell |
5,091
-947
| -16% | -$145K | 0.06% | 55 |
|
|
2022
Q1 | $979K | Buy |
6,038
+3
| +0% | +$436 | 0.07% | 51 |
|
|
2021
Q4 | $817K | Buy |
6,035
+261
| +5% | +$30.8K | 0.06% | 58 |
|
|
2021
Q3 | $623K | Sell |
5,774
-200
| -3% | -$22.9K | 0.05% | 67 |
|
|
2021
Q2 | $673K | Buy |
5,974
+291
| +5% | +$32.8K | 0.05% | 64 |
|
|
2021
Q1 | $615K | Hold |
5,683
| – | – | 0.06% | 61 |
|
|
2020
Q4 | $609K | Buy |
5,683
+19
| +0.3% | +$1.83K | 0.06% | 59 |
|
|
2020
Q3 | $496K | Sell |
5,664
-436
| -7% | -$41K | 0.06% | 61 |
|
|
2020
Q2 | $599K | Sell |
6,100
-393
| -6% | -$34.6K | 0.07% | 54 |
|
|
2020
Q1 | $495K | Buy |
6,493
+1,773
| +38% | +$151K | 0.07% | 59 |
|
|
2019
Q4 | $418K | Sell |
4,720
-100
| -2% | -$8.3K | 0.05% | 72 |
|
|
2019
Q3 | $365K | Buy |
4,820
+186
| +4% | +$12.8K | 0.04% | 76 |
|
|
2019
Q2 | $337K | Buy |
4,634
+303
| +7% | +$23.8K | 0.04% | 78 |
|
|
2019
Q1 | $349K | Sell |
4,331
-100
| -2% | -$8.18K | 0.04% | 75 |
|
|
2018
Q4 | $408K | Buy |
4,431
+1,867
| +73% | +$164K | 0.06% | 68 |
|
|
2018
Q3 | $243K | Buy |
+2,564
| New | +$243K | 0.03% | 90 |
|
|
2015
Q3 | – | Sell |
-135,157
| Closed | -$9.08M | – | 96 |
|
|
2015
Q2 | $9.08M | Sell |
135,157
-3,548
| -3% | -$232K | 1.59% | 29 |
|
|
2015
Q1 | $8.12M | Sell |
138,705
-3,104
| -2% | -$188K | 1.46% | 31 |
|
|
2014
Q4 | $9.28M | Sell |
141,809
-6,265
| -4% | -$395K | 1.68% | 28 |
|
|
2014
Q3 | $8.55M | Sell |
148,074
-4,865
| -3% | -$270K | 1.7% | 28 |
|
|
2014
Q2 | $8.63M | Sell |
152,939
-331,099
| -68% | -$17.4M | 1.75% | 28 |
|
|
2014
Q1 | $24.9M | Sell |
484,038
-9,405
| -2% | -$475K | 1.83% | 29 |
|
|
2013
Q4 | $26.1M | Buy |
493,443
+335,984
| +213% | +$16.5M | 2.01% | 26 |
|
|
2013
Q3 | $7.04M | Buy |
157,459
+13,518
| +9% | +$599K | 1.8% | 29 |
|
|
2013
Q2 | $5.95M | Buy |
+143,941
| New | +$6.3M | 1.58% | 33 |
|
Other funds holding ABBV
Chas P. Smith & Associates (CPS)'s ABBV Position: Q1 2026 in Review
Chas P. Smith & Associates (CPS) held its AbbVie (ABBV) position steady in Q1 2026 at 4,249 shares worth $924K. The position accounts for 0.05% of the portfolio, ranked #78.
Chas P. Smith & Associates (CPS) first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. The position peaked at $26.1M in Q4 2013. 4,098 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Chas P. Smith & Associates (CPS) held 4,249 shares of AbbVie worth $924K as of Q1 2026.
- Chas P. Smith & Associates (CPS) left its AbbVie share count unchanged in Q1 2026.
- AbbVie made up 0.05% of Chas P. Smith & Associates (CPS)'s portfolio in Q1 2026, its #78 holding.
- Chas P. Smith & Associates (CPS) first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
- Chas P. Smith & Associates (CPS)'s AbbVie position peaked at $26.1M in Q4 2013.
- 4,098 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Chas P. Smith & Associates (CPS)'s 13F filing for Q1 2026, filed 12 May 2026.